- Email: [email protected]
4888169 Bordetella bronchiseptica vaccine
PATENT ABSTRACTS 4886782 MALARIAL
IMMUNOGEN
Michael A Good, Ja Berzofsky, Louis H Miller assigned to The United States of America as represented by the Department of Health and Human Services The circumsporozoite (CS) protein of Plasmodium falciparum has been analyzed to develop a new anti-sporozoite malarial vaccine, Localization of sites for T-cell recognition on this molecule is critical for vaccine design. By using an algorithm designed to predict T-cell sites and a large panel of H-2 congenic mice, a major nonrepetitive T-cell was located. When a synthetic peptide corresponding to this site was covalently linked to the major B-cell site on the molecule, an immunogen capable of eliciting a high titer antibody response was formed. This peptide sequence is capable of priming helper Tcells for a secondary response to the intact CS protein. This site represents the first helper T-cell site described for the CS molecule outside of the repetitive region, and is a major immunodominant T-site on the molecule. The approach described herein is useful in the rational design and construction of more efficacious vaccines.
4888163 DIAGNOSTIC AGENT FOR BREAST CANCER OR TUMOR Akiko Kubodera, Touichi Tanaka, Yukimichi Komori, Chiba, Japan assigned to Nihon MediPhysics Co Ltd A radioactive diagnostic agent for imaging a breast cancer or tumor, which comprises an antiestriol-3-sulfate antibody labeled with a radioisotope as an essential component,
4888169 BORDETELLA
445
4888170 VACCINES OBTAINED FROM ANTIGENIC GENE PRODUCTS OF RECOMBINANT GENES Roy Curtiss assigned to Research Corporation This invention relates to a vaccine for the iramunization of a vertebrate, comprising: an avirulent derivative o f a pathogenic microbe that expresses a recombinant gene derived from a pathogen of said vertebrate it being provided that said avirulent microbe does not normally exchange genetic material with said pathogen, to produce an antigen capable of inducing an iramune response in said vertebrate against said pathogen.
4888279 NOVEL IMMUNOSORBENT ASSAYS EMPLOYING ANTIBIOTIC KEYING AGENTS Allen R Zeiger assigned to Thomas Jefferson University New immunosorbent enzyme assays are provided employing antibiotic keying agents for binding a molecular species to be detected to a test surface followed by binding of an antibody specific for the species and detection of the antibody-species binding. In accordance with preferred embodiments, soluble peptidoglycan is assayed in a fluid binding it to a test surface with vancomycin, reacting the bound material with a peptidoglycan specific antibody, and measuring the extent of the antibody reaction. Assessment of bodily fluids and fermenation broths for the presence of certain kinds of antibiotics is one object of this invention. Assessment of sera for the presence of antibodies that have specificity for soluble peptidoglycans is another object of this invention. Assessment of bodily states in maremals is another object of the invention.
BRONCHISEPTICA
VACCINE Albert Brown, Joseph C Frantz, Richard H Peetz assigned to Norden Laboratories Inc A vaccine for protecting canines against infection by Bordetella bronchiseptica is prepared by inactivating whole cells with glutaraldehyde,
4888281 METHOD OF CATALYZING CHEMICAL REACTIONS Geral Schochetman, Richard J Massey assigned to Igen Inc
IMMUNOGEN
Michael A Good, Ja Berzofsky, Louis H Miller assigned to The United States of America as represented by the Department of Health and Human Services The circumsporozoite (CS) protein of Plasmodium falciparum has been analyzed to develop a new anti-sporozoite malarial vaccine, Localization of sites for T-cell recognition on this molecule is critical for vaccine design. By using an algorithm designed to predict T-cell sites and a large panel of H-2 congenic mice, a major nonrepetitive T-cell was located. When a synthetic peptide corresponding to this site was covalently linked to the major B-cell site on the molecule, an immunogen capable of eliciting a high titer antibody response was formed. This peptide sequence is capable of priming helper Tcells for a secondary response to the intact CS protein. This site represents the first helper T-cell site described for the CS molecule outside of the repetitive region, and is a major immunodominant T-site on the molecule. The approach described herein is useful in the rational design and construction of more efficacious vaccines.
4888163 DIAGNOSTIC AGENT FOR BREAST CANCER OR TUMOR Akiko Kubodera, Touichi Tanaka, Yukimichi Komori, Chiba, Japan assigned to Nihon MediPhysics Co Ltd A radioactive diagnostic agent for imaging a breast cancer or tumor, which comprises an antiestriol-3-sulfate antibody labeled with a radioisotope as an essential component,
4888169 BORDETELLA
445
4888170 VACCINES OBTAINED FROM ANTIGENIC GENE PRODUCTS OF RECOMBINANT GENES Roy Curtiss assigned to Research Corporation This invention relates to a vaccine for the iramunization of a vertebrate, comprising: an avirulent derivative o f a pathogenic microbe that expresses a recombinant gene derived from a pathogen of said vertebrate it being provided that said avirulent microbe does not normally exchange genetic material with said pathogen, to produce an antigen capable of inducing an iramune response in said vertebrate against said pathogen.
4888279 NOVEL IMMUNOSORBENT ASSAYS EMPLOYING ANTIBIOTIC KEYING AGENTS Allen R Zeiger assigned to Thomas Jefferson University New immunosorbent enzyme assays are provided employing antibiotic keying agents for binding a molecular species to be detected to a test surface followed by binding of an antibody specific for the species and detection of the antibody-species binding. In accordance with preferred embodiments, soluble peptidoglycan is assayed in a fluid binding it to a test surface with vancomycin, reacting the bound material with a peptidoglycan specific antibody, and measuring the extent of the antibody reaction. Assessment of bodily fluids and fermenation broths for the presence of certain kinds of antibiotics is one object of this invention. Assessment of sera for the presence of antibodies that have specificity for soluble peptidoglycans is another object of this invention. Assessment of bodily states in maremals is another object of the invention.
BRONCHISEPTICA
VACCINE Albert Brown, Joseph C Frantz, Richard H Peetz assigned to Norden Laboratories Inc A vaccine for protecting canines against infection by Bordetella bronchiseptica is prepared by inactivating whole cells with glutaraldehyde,
4888281 METHOD OF CATALYZING CHEMICAL REACTIONS Geral Schochetman, Richard J Massey assigned to Igen Inc